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Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) Wnt signaling molecules have been implicated in mouse mammary carcinogenesis.
1-catenin, a downstream molecule in the Wnt pathway, activates transcription of target genes. Our studies are aimed at determining whether 3-catenin can function as an oncogene in the mammary gland.
Using the mouse as a model system, we targeted expression of P-catenin to the mammary gland in transgenic animals.
Our results show that transgenic females develop mammary gland hyperplasia, with the majority of them proceeding to develop mammary gland tumors.
The 3-catenin tumors are characterized as microacinar adenocarcinomas, nearly identical to those found in Wnt-induced mouse models.
We were also interested in identifying downstream transcriptional targets of 3-catenin in the mammary gland.
We have found cyclin Dl and c-myc, targets previously identified in other systems, to be upregulated in P-catenin mammary tumors and tumor cell lines.
In an attempt to identify novel targets of 3-catenin, mammary cell lines expressing inducible or constitutively activated f-catenin were generated, and a whole genome screen appoach was taken. Several novel candidate target genes have been identified.
Thus, our studies establish 1-catenin as an oncogene in the mammary gland and have aided in the identification of gene targets in 3-catenin-mediated mammary oncogenesis.
Body
The Wnt signal transduction pathway has been shown to play a causative role in breast cancer in the mouse. j3-catenin, which functions downstream in the Wnt signal transduction pathway, has been implicated in many types of human cancers. We were interested in determining whether 13-catenin may play a role in mammary tumorigenesis. In an attempt to test whether 1-catenin can function as an oncogene in the mammary gland, the mouse was chosen as a model system and a transgenic approach was taken.
An MMTV-promoter was used to target expression of a constitutively active form of P-catenin, lacking the 90 amino-terminal amino acids of the protein Genetic collaboration in mammary oncogenesis, whereby two oncogenes together vastly accelerate the onset of tumorigenesis, has been observed in several instances. In particular, in mice bearing both MMTV-Wnt-1 and MMTV-Int-2 (Fgf3) transgenes, onset of tumors is significantly more rapid as compared to mice harboring only a single transgene. Given 13-catenin's role in the Wnt pathway, we are interested in testing whether P3-catenin can collaborate with Fgf3 in accelerating tumorigenesis. Double transgenics, carrying both constitutively active P3-catenin and Fgf3 transgenes expressed in the mammary gland, were generated and monitored for appearance of tumors. An accelerated tumorigenic phenotype has been observed in double transgenic animals, suggesting that the P3-catenin pathway specifically collaborates with Fgf-3 in mammary gland tumorigenesis.
A second P3-catenin trangenic mouse model has also been generated. An MMTV-promoter was used to drive expression of a carboxy-terminal truncated form of P-catenin (AC) to the mammary gland. The C-terminal truncation deleted the carboxy-terminal putative transactivation domain, thought to be required for activation of downstream targets. Three j3-cateninAC transgenic lines were generated, all of which express the transgene in the pregnant mammary gland.
The highest expressing transgenic line, AC-3035 was chosen to be bred with MMTV-Wnt-1 transgenic mice. Double transgenic mice were generated and monitored for appearance of mammary tumors. The expectation was that Wnt-1 mediated mammary tumorigenesis might be halted or at least delayed due to the presence of a C-terminally deleted j3-catenin molecule. Interestingly, however, double transgenics were found to have significantly increased rates of tumorigenesis, in contrast to what was expected. Further analysis is being carried out in the laboratory in an attempt to explain this interesting, yet unanticipated, finding.
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In an attempt to enable further dissection of the molecular pathways involved in 13-catenin-mediated mammary tumorigenesis, tumor cell lines were generated from the P3-catenin-AN mammary tumors. Several tumor cell lines were generated, all of which expresses moderate to high levels of the transgene, as clones stably expressing high levels of P-catenin have also been generated.
Ultimately, the 13-catenin-derived tumor cell lines will be used as an additional means to verify targets and will further provide the opportunity to demonstrate the relevance of these targets to tumorigenesis in vivo.
The studies outlined here provide convincing evidence that 13-catenin plays a causative role in mammary gland tumorigenesis. Furthermore, these results support the notion that the tumorigenicity associated with the Wnt signal transduction pathway is mediated by 13-catenin. These studies also demonstrate that c-myc and cyclin DI are likely targets of 13-catenin in the mammary gland, and have also provided the basis for identification of novel targets of P3-catenin in the mammary gland. Taken together, this work has helped to elucidate the role of P3-catenin in mammary gland tumorigenesis. Recently, it was shown that upregulated levels of P3-catenin have been found in human breast tumors. Our studies are thus of particular significance since they demonstrate a causative role for P3-catenin in breast cancer. In addition, our work has aided in dissecting the genetic and biochemical pathways responsible for the oncogenic nature of P3-catenin.
Oncogene (2001) The Wnt signal transduction pathway has been implithrough the membrane-bound Frizzled receptor and cated in mammary tumorigenesis in the mouse. /3-catenin, subsequently through Disheveled, facilitating inhibition a key downstream effector of this pathway interacts with of GSK3/3. The net result of the Wnt signal is and thus activates the Tcf/Lef family of transcription cytoplasmic accumulation of /3-catenin and entry of factors. Elevated levels of /3-catenin have been found in /3-catenin into the nucleus. Once in the nucleus, /3-many human tumors, notably colon carcinomas. Recatenin associates with Tcf/Lef transcription factors cently, elevated levels of /3-catenin have been associated and together these activate downstream targets. Downwith poor prognosis in human adenocarcinoma of the regulation of /3-catenin levels in the nucleus likely breast. In order to assess the possible role of /3-catenin in occurs via nuclear export by APC, as recently reported mammary carcinoma, we have created transgenic mice (Henderson, 2000; Neufeld et al., 2000;  Rosinbearing the MMTV-LTR driving an activated form of Arbesfeld et al., 2000) . /3-catenin. These mice develop mammary gland hyperStructure-function analyses of /3-catenin and its plasia and mammary adenocarcinoma, a phenotype very Drosophila homolog, Armadillo, have been informasimilar to that of transgenic mice expressing an MMTVtive. Amino-terminal deletion mutants were shown to driven Wnt gene. Indeed, the histopathology of the have increased stability due to loss of GSK phosphormammary tumors in Wnt-mediated adenocarcinoma is ylation residues Munemitsu et al., identical to that observed in our /3-catenin-mediated 1996). The central portion of fl-catenin, comprised of disease model. Furthermore, putative fl-catenin transcrip-12 armadillo repeats, facilitates multiple protein tional targets, cyclin D1 and c-myc, are elevated in /3-interactions, including binding to Tcf/Lef, APC, Ecatenin-mediated mammary tumors and cell lines. These cadherin and i-catenin terminal portion of the protein (Hsu et al., 1998) . Wnt; adenocarcinoma; MMTV A correlation between /3-catenin and tumorigenesis has been well established (reviewed in Polakis (2000)). Mutations and deletions of phosphorylation sites in the Introduction amino terminus resulting in stabilization of /3-catenin have been identified in numerous human tumors and /3-catenin has a diverse set of functions within the cell.
cancer cell lines, including colon, hepatocellular, In its capacity to bind components of the actin ovarian, endometrial and others (reviewed in Polakis cytoskeleton, namely E-cadherin and o-catenin, /3- (2000) ). Elevated /3-catenin levels resulting from catenin plays a role in cell adhesion (reviewed in mutations in other components of the Wnt signaling Bullions and Levine (1998) ). /3-catenin is also an pathway, such as loss-of-function APC mutations, are integral player in the Wnt signal transduction pathway also commonly found. In colon cancer, it is estimated (reviewed in Polakis (1999 Polakis ( , 2000 ). In a resting cell, /3-that nearly 85% of tumors contain mutations in APC, catenin is phosphorylated by glycogen synthase kinasewith a majority of the remainder containing activating 3/3 (GSK) in association with adenomatous polyposis /3-catenin mutations (Kinzler and Vogelstein, 1996; coli (APC) protein, an event which targets /3-catenin Morin ei al., 1997) . Mouse models of /3-catenin for ubiquitination and subsequent degradation. In overexpression have recently been generated in an response to extracellular Wnt, a signal is transduced attempt to show a causative role for /3-catenin in the onset of tumorigenesis. Gat et al. (1998) demonstrated that mice expressing K14-driven /3-catenin (AN87) intestinal polyps, although increased branching of the MMTV promoter placed upstream of a truncated /3 intestinal villi was observed (Wong et al., 1998) . In a catenin cDNA lacking the first 90 codons (fl-cateninsubsequent study, intestinal polyps were observed when AN90) tagged with a 3'-KT3 epitope followed by an f3-catenin (Aex3) was introduced into the endogenous SV40 polyadenylation (polyA) site. Following injection /3-catenin locus by homologous recombination (Harada of the construct into the male pronucleus of embryos et al., 1999) . and transfer to pseudopregnant foster mothers, 44 pups The mammalian transcriptional targets of fl-catenin were born. From these, four transgenic founder mice are beginning to be elucidated. Using SAGE analysis, were identified by Southern blot analysis using a probe c-myc was identified as a target of the pathway in for SV40 polyA. All four founder mice passed the human colorectal cells Figure  1988 ). Mammary tumors were also observed in lb). Analysis of transgene expression in a range of heterozygous APCMý" mice (Moser et al., 1993) .
tissues derived from MMTV-flcatAN.A mice reveals Regarding /3-catenin, a recent study indicates that f3-the highest levels of expression in the mammary gland, catenin activity in human breast tumors correlates with with low levels of expression in a limited number of elevated expression of cyclin Dl as well as a poor other tissues, including testis and skeletal muscle prognosis (Lin et al., 2000) . A causative role for /3-( Figure Ic) . In MMTV-/3catAN.B, transgene expression catenin in mammary tumorigenesis, however, has not is detected exclusively in the mammary gland ( Figure  been established. ld), albeit at lower levels than in MMTV-/3catAN.A. In this study, we explore directly whether /3-catenin Thus, the MMTV promoter reliably directs expression can induce mammary tumorigenesis and, thus, could of the /3-cateninAN90 transgene to the mammary gland serve as a downstream effector of the Wnt pathway. To in MMTV-flcatAN mice. that end, we have generated transgenic mice expressing an activated form of /3-catenin in the mammary gland
Manimary gland hyperplasia in MMTV-/3catAN (MMTV-flcatAN). We find that MMTV-flcatAN mice,
Mam rg land mic e like mice bearing a Wnt transgene, exhibit hyperplasia transgenic mice of the mammary gland. Furthermore, MMTV-/3catAN
Whole mount analysis was performed to examine the mice develop malmnary adenocarcinomas, with a ductal structure of mammary glands in MMTVhistopathology that is identical to that found in /3catAN transgenic mice. As shown in Figure .
"%-%.
Both Wnt-l and Wnt-10b males further proceed to
Eph4
develop mammary adenocarcinomas, albeit at a relatively low frequency Tsukamoto el al., 1988) . In contrast, whole mount * analysis revealed only rudimentary epithelial buds in "0o: We have generated a mouse model in which an GAPDH activated form of /3-catenin (MMTV-/3catAN) is overexpressed in the mammary gland. Our findings provide adefinitive de mmotrylatond. tt fendings c Figure 6 Transcriptional targets are upregulated in fl-catenin provide a definitive demionstration that fl-catenin can tumor cell lines. Northern blot analysis of RNA isolated from a induce mammary tumorigenesis. Previously, overnormal mammary epithelial cell line, Eph4, and from fl-catenin expression of upstream components of the Wnt signal mammary tumor cell lines
